Stock Ratings / Health Care / NXL / forecast

NUWE (45) VBIO (44) NDRA (48) IRIX (34) ⌘ Pro Terminal →

Nexalin Technology Inc. (NXL) 12-Month Stock Forecast & Price Target Cone

Q: Is NXL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nexalin Technology Inc. (NASDAQ: NXL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.63 (0.00% 1D, market cap $1.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NXL ranks #770 in composite RQD confidence.

Q: How does NXL compare to NUWE and VBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NXL carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 79.7%, and ROIC of -35.0%. By comparison, NUWE (Nuwellis Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and VBIO (Valion Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.3M). Among the 5-stock peer group, NXL leads on earnings multiple (N/A) while NXL leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for NXL?

Per NXL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001527352), Nexalin Technology Inc. generated $301.6K in revenue (+78.8% YoY), -$8.2M in net income, and -$5.0M in free cash flow against $4.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is NXL trading relative to its 50-day, 200-day, and 52-week technical levels?

NXL last traded at $1.63 (0.00% on volume of 11,806 shares), positioning the stock -64.64% below its 50-day simple moving average ($4.61) and -85.05% below its 200-day simple moving average ($10.90). Across its 52-week range of $1.51 to $45.00, NXL sits at the 0.3% percentile with a 14-day RSI of 26.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.43 to $1.83).

Q: What is NXL's 12-month stock price target?

Nexalin Technology Inc. (NXL) carries a 12-month consensus base price target of $1.48 (-9.2% from $1.63), with a bull-case target of $47.25 and a bear-case floor of $1.15.

Q: Is NXL stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NXL D- (Sell — SELL) with an RQD Confidence score of 37/100.

$1.63 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.63

Nexalin Technology Inc. (NXL) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.63 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NXL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY NXL SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (22% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.63-35.3% Next Q

Q2 (-2Q)

Grade D$2.35-20.9% Next Q

Q3 (-1Q)

Grade D$1.86-12.4% Next Q

Current

Grade D-$1.63-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NXL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NXL currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.61) and Max Pain ($1.71) forces dealer call-delta covering toward $47.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NXL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NXL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NXL Position Size: $10,000

Shares at $1.63: 6135.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $1.15

$7,055

$-2,945 (-29.4%)

12M Consensus BaseTarget $1.48

$9,080

$-920 (-9.2%)

12M Bull Case BreakoutTarget $47.25

$289,877

+$279,877 (+2798.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$2	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$44	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NXL)

✓Walkthrough of NXL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NXL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -84.69%🛡️ HOLDING TREND SUPPORT

2026-10-30O $1.60H $1.63L $1.51C $1.63VOL 21.1K

RES: $8.95SUP: $0.57SMA50: $4.61SMA200: $10.90

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NXL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NXL Butterfly Map → + Track NXL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +78.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NXL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NXL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NXL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NXL)

Health Care Rank #770 of 1016 ⚔️ NUWE vs NXL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NXL vs. NUWE, VBIO, NDRA, IRIX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nexalin Technology Inc. (NXL) ranks #770 by composite RQD confidence (37/100, grade D-) and #1000 by equity capitalization ($1.9M). Within this direct 5-issuer industry benchmark cohort, NXL leads on earnings valuation at N/A trailing P/E, while NXL leads on capital efficiency and profitability with -35.0% ROIC and 79.7% gross margin. NDRA currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with NXL at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NXL ACTIVE Nexalin Technology Inc.	D-	37/100	—	79.7%	-35.0%	0.00%	$1.9M	Benchmark Subject
NUWE Nuwellis Inc.	D	45/100	—	62.0%	-35.0%	+2.12%	$2.3M	/nuwe-vs-nxl →
VBIO Valion Bio Inc.	D	44/100	—	—	-35.0%	-9.13%	$1.3M	/vbio-vs-nxl →
NDRA ENDRA Life Sciences Inc.	D	48/100	—	—	-35.0%	+2.95%	$7.3M	/ndra-vs-nxl →
IRIX IRIDEX Corporation	E	34/100	—	36.5%	-35.0%	-2.92%	$12.7M	/irix-vs-nxl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001527352

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nexalin Technology Inc. (NXL) reported GAAP revenue of $301.6K (+78.8% vs. FY2024 revenue of $168.7K , and +172.4% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$5.0M, and free cash flow of -$5.0M (-25.7% YoY). On the balance sheet, NXL closed FY2025 with $4.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$301.6K	-$8.2M	-$5.0M	-$5.0M	$4.6M	—
FY2024 (FY)	2024-12-31	$168.7K	-$7.6M	-$3.9M	-$3.9M	$4.2M	—
FY2023 (FY)	2023-12-31	$110.7K	-$4.6M	-$3.8M	-$3.8M	—	—

3. NXL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NXL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nexalin Technology Inc. (NASDAQ: NXL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.63 (0.00% 1D, market cap $1.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NXL ranks #770 in composite RQD confidence.

How does NXL compare to NUWE and VBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NXL carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 79.7%, and ROIC of -35.0%. By comparison, NUWE (Nuwellis Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and VBIO (Valion Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.3M). Among the 5-stock peer group, NXL leads on earnings multiple (N/A) while NXL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NXL?

Per NXL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001527352), Nexalin Technology Inc. generated $301.6K in revenue (+78.8% YoY), -$8.2M in net income, and -$5.0M in free cash flow against $4.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NXL trading relative to its 50-day, 200-day, and 52-week technical levels?

NXL last traded at $1.63 (0.00% on volume of 11,806 shares), positioning the stock -64.64% below its 50-day simple moving average ($4.61) and -85.05% below its 200-day simple moving average ($10.90). Across its 52-week range of $1.51 to $45.00, NXL sits at the 0.3% percentile with a 14-day RSI of 26.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.43 to $1.83).

NXL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NXL's 12-month stock price target?

Nexalin Technology Inc. (NXL) carries a 12-month consensus base price target of $1.48 (-9.2% from $1.63), with a bull-case target of $47.25 and a bear-case floor of $1.15.

Is NXL stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NXL D- (Sell — SELL) with an RQD Confidence score of 37/100.

Direct Sub-Reports: NXL RQD Cockpit NXL 12M Forecast NXL Earnings & Move NXL Dividends & DRIP NXL Insiders & 13F NXL Whale Options NXL Profit Sankey NXL News & Why